For decades, the heart of University Circle was lifeless after 5 p.m. Uptown, a $65 million development of new shops, restaurants, markets and apartments, aimed to change that by becoming a new center of gravity for Cleveland’s cultural district. So, now that it’s halfway completed, how is Uptown doing?

Cleveland Clinic Innovations (CCI) has named seasoned Health Information Technology (HIT) veteran Gary Fingerhut as its new executive director. Fingerhut has more than 30 years of experience as an entrepreneur in IT, co-founding a global software company and as a senior executive of a software development and technology consulting firm.

CCI is the commercial arm of the Cleveland Clinic, responsible for company creation and business development of medical technology developed by its doctors and researchers.

For the past three years, Fingerhut has served as general manager of IT commercialization for CCI, a position he will continue to perform in addition to his new executive director duties.
 
HIT makes up 23 percent of Innovations’ business, up from six percent when Fingerhut started with the organization. “I take credit for being part of a team,” Fingerhut says of the growth. “We’re a very collaborative group here: very dedicated, very focused in bringing products to market that will change lives. You can’t ask for a better role than that as executive director.”
 
Fingerhut plans to continue that growth in his new position. “I’m really heavily focused on inventor satisfaction as a key goal,” he says. “And I would like to see our Innovation Alliance grow considerably.”
 
And, of course, Fingerhut wants to improve care through technology. “Everything we do is focused on better patient care,” he says. “But we’re also focused on growth in Ohio. Since we began in 2000, we’ve created 1,100 jobs in Northeast Ohio and 66 spinoff companies.”
 
Fingerhut is a Cleveland native and has raised five children here. “This is an incredible institution and I’m really honored to be a part of it,” he says. “We take innovation seriously here, and I look forward to really making a difference.”

 
Source: Gary Fingerhut
Writer: Karin Connelly

If you were among the thousands of people who attended concerts this summer outside the Transformer Station in Ohio City, you have Thomas Welsh to thank. As director of the Cleveland Museum of Art's newly minted City Stages, the Philadelphia native is spicing up his new hometown with musical acts from around the globe.

Once ground zero for all things rock 'n' roll, Cleveland has steadily shed its reputation as King, and in the process squandered many of the economic benefits that go along with it. An effort by local advocates is attempting to change that by raising the industry’s profile and marketing it to a wider audience.

Abeona Therapeutics, a small biotech startup company that develops therapies for lysomal storage diseases, earned the Global Gene’s Champion of Hope award, along with its partners, for its work in developing therapies for children with Sanfilippo Syndrome, a rare genetic disorder.
 
Abeona, founded earlier this year in Cleveland as a spinoff of Columbus-based Nationwide Children’s Hospital, is developing two products that came out of research at Nationwide. ABX-A and ABX-B have the potential to cure Sanfilippo Syndrome.
 
Children with Sanfilippo are missing an essential enzyme for normal cellular function, causing toxins in their brains and bodies to cause severe disabilities. Symptoms often appear in the first year of life, causing progressive muscular and cognitive decline, and the disease is usually fatal by the early teens.
 
Current studies show that a single dose of Abeona’s treatments prompted cells to produce the missing enzymes and help repair the damage.
 
“What’s unique about this drug is that it’s a collaboration between Abeona, the hospital and eight international foundations to find a treatment for Sanfilippo Syndrome,” says Abeona president and CEO Tim Miller.
 
Abeona’s products are a result of 10 years of research done by Nationwide’s Haiyan Fu. Abeona is currently raising money to conduct phase I and II clinical trials in 2014. “One of the things that drew me to this company is the pre-clinical data for these drugs,” says Miller. “The life span is improved. If this transfers over to the kids I’ll be very excited.”
 
While there are no approved treatments for Sanfilippo Syndrome yet, Miller says a number of companies are working on therapies.

 
Source: Tim Miller
Writer: Karin Connelly
 

Once the province of sculptors, public art has evolved into an essential element of urban placemaking and social engagement. From murals on vacant buildings to art in laundromats to edible art installations that are as mouthwatering as they are aesthetically pleasing, we take a look at how public art is transforming our cities.

“We’re shifting because the times are shifting,” says Grace Gallucci of NOACA, adding that the planning agency will shift its focus to multimodal transportation, developing a fix-it-first approach that prioritizes existing infrastructure over new road projects, and basing funding decisions on their regional economic development impact.

The Cleveland Clinic marks its 50th year of successful kidney transplants this year. While the Clinic was not the first to successfully transplant a human kidney, the hospital was, and continues to be, a pioneer in the field.

“There were two earlier transplants,” explains Robert Heyka, interim chair of the department of nephrology and hypertension at the Clinic’s Glickman Urological and Kidney Institute. “One was in New Jersey, but it only lasted 10 months. The first successful transplant was in 1954, in Boston, which worked because the transplant occurred with identical twins.”
 
The Cleveland Clinic performed its first successful kidney transplant in 1963, in part due to the development of anti-rejection drugs, and in part because Willem Kolff, a doctor from the Netherlands, came to the Clinic in the 1950s with his dialysis machine.
 
Kolff’s original dialysis machines were made with a washing machine motor, a nose cone borrowed from NASA and peach cans. He perfected his machine at the Clinic. Dialysis made it possible to keep patients alive while they waited for a transplant. “A combination of medications and the Cleveland Clinic having dialysis machines made the program successful,” says Heyka.
 
In 1966, the Cleveland Clinic performed 126 kidney transplants. Additionally, Cleveland was one of the first cities to establish an independent organ procurement program in the late 1960s. The organization now is known as Lifebanc.
 
Today, the Clinic has transplanted more than 4,200 kidneys and is on track to perform 200 transplants this year. The Glickman Urological and Kidney Institute ranked second this year in U.S. News and World Report’s America’s Best Hospitals.
 
“All these things we take for granted now as standard and mass produced,” says Heyka. “When you get into it, it’s more inspiring when you hear about the people who did it first and the challenges they had to face.”

 
Writer: Karin Connelly
Source: Robert Heyka

Starting a successful food-based business takes more than a great idea and the ability to cook. Like any entrepreneurial venture, food startups require planning, money and a willingness to be flexible. But those who do dive in have found there's plenty of guidance, support and collaboration in the local food startup community.

WMMS "The Buzzard" reached the largest radio audience in the history of Cleveland media. A new film hopes to document the glory years when a charmed roster of on-air talent introduced national rock acts like Bruce Springsteen, David Bowie and Joe Walsh to the people of Cleveland and the rest of the country.

Researcher J. Mark Brown and his team at the Cleveland Clinic Lerner Research Institute have discovered a protein that might promote obesity and diabetes. Therefore, blocking that protein, called ABHD6, might prevent these diseases.

ABHD6 regulates the brain’s endocannabinoid system, which is involved in metabolism, cravings and hunger.
 
Brown discovered ABHD6’s role in fat storage while studying a mutation in a different protein in the same group, ABHD5. “Normally, fat is stored in triglyceride tissue,” Brown explains. “With abnormal ABHD5, fat is stored in every other cell in the body. In studying that we discovered a crucial breakdown in ABHD6 and we decided to study it.”
 
Brown conducted a study in mice to see how fat was stored in ABHD6, to see if it impacted type-2 diabetes, obesity and fatty liver disease. He found that blocking the protein’s function had a direct impact on these diseases.
 
The research indicates that blocking function of ABHD6 in mice protects against all diseases driven by eating a high-fat diet. Further research could actually lead to a pill that would block ABHD6, and therefore prevent obesity.
 
Brown’s findings were published last week in the journal Cell Reports. “Our paper will be the first that shows the importance of the enzyme in regulating the way the body stores fat,” explains Brown, who has spent the past four years researching ABHD6.
 
“It’s hard to say if it would ever end up being a magic pill to cure obesity,” says Brown. “We look at it like a preventative measure. We’re really excited to move forward with it and conduct safety trials with humans. We know it works in mice, so it’s very important to translate our findings into human studies as quickly as we can.”

 
Source: J. Mark Brown
Writer: Karin Connelly